Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-hydroxy-2-(3-pyridyl)ethylidene Diphosphonate
2. 2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate
3. 2-(3-pyridinyl)-1-hydroxyethylidenebisphosphonate
4. Actonel
5. Atelvia
6. Bisphosphonate Risedronate Sodium
7. Risedronate
8. Risedronate Sodium, Bisphosphonate
9. Risedronic Acid
10. Risedronic Acid, Monosodium Salt
11. Sodium, Bisphosphonate Risedronate
1. Sodium Risedronate
2. 115436-72-1
3. Actonel
4. Atelvia
5. Risedronate (sodium)
6. Ne 58095
7. Risedronic Acid Monosodium Salt
8. Risedronate Monosodium
9. Ofg5exg60l
10. Risedronate Sodium Anhydrous
11. Ne-58095 Anhydrous
12. Sodium Trihydrogen (1-hydroxy-2-(3-pyridyl)ethylidene)diphosphonate
13. 115436-72-1 (sodium)
14. Risedronic Acid Sodium
15. Benet
16. Nsc-722598
17. Nsc-759280
18. Actonel (tn)
19. Phosphonic Acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, Monosodium Salt
20. Sodium Hydrogen (1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl)phosphonate
21. Risedronate Sodium [usan]
22. Risedronic Acid Sodium Salt
23. Mfcd00867080
24. 122458-82-6
25. Unii-ofg5exg60l
26. Optinate
27. Acrel
28. Risedronate Sodium [usan:usp]
29. Sodium Hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate
30. Optinate Septimum
31. Monosodium Risedronate
32. Monosodium (1-hydroxy-2-(3-pyridinyl)ethylidene)bisphosphonate
33. Ne 58095 Sodium
34. Risedronate Sodium (usp)
35. Chembl1654
36. Schembl18377
37. Risedronate Sodium, Min 97%
38. Chebi:8868
39. Dtxsid20924178
40. Risedronate Sodium [vandf]
41. Risedronate Sodium [mart.]
42. Act03362
43. Bcp22742
44. Hy-b0119
45. Risedronate Sodium [usp-rs]
46. Risedronate Sodium [who-dd]
47. Ac-732
48. Mfcd01706268
49. S1428
50. Akos015833432
51. Ab09807
52. Ccg-213235
53. Cs-1883
54. Nsc 722598
55. Nsc 759280
56. Risedronate Sodium [orange Book]
57. Ncgc00346521-01
58. Ac-20120
59. As-13309
60. Risedronate Sodium [usp Monograph]
61. Ft-0631078
62. M2289
63. Risedronic Acid Monosodium Salt [mi]
64. D00942
65. H11438
66. Ab01274790-01
67. Q-201723
68. Q27285633
69. 2-(3-pyridinyl)-2-hydroxyethylidene-1,1-bisphosphonate
70. Monosodium 1-hydroxy-2-(3-pyridyl)ethylidene-1,1-diphosphonate
71. 1-hydroxy-2-(3-pyridinyl) Ethylidene Bis-phosphonic Acid Monosodium Salt
72. Hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate (na+)
73. P,p'-[1-hydroxy-2-(3-pyridonyl)ethylidene]bis-phosphonic Acid Sodium Salt
74. Phosphonic Acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, Disodium Salt
75. Phosphonic Acid, (2-hydroxy-2-(3-pyridinyl)ethylidene)bis-, Disodium Salt
76. Risedronate Sodium, United States Pharmacopeia (usp) Reference Standard
77. Risedronate Sodium;risedronic Acid Sodium;ne-58095; Ne 58095; Ne58095
78. Sodium Hydrogen-1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethylphosphonate
79. Sodium;hydroxy-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphinate
80. (1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)bis(phosphonic Acid) Sodium Salt
81. Risedronate Sodium 2.5-hydrate, European Pharmacopoeia (ep) Reference Standard
82. Risedronate Sodium, Pharmaceutical Secondary Standard; Certified Reference Material
83. 934544-85-1
| Molecular Weight | 305.09 g/mol |
|---|---|
| Molecular Formula | C7H10NNaO7P2 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 304.98301994 g/mol |
| Monoisotopic Mass | 304.98301994 g/mol |
| Topological Polar Surface Area | 151 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 375 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 6 | |
|---|---|
| Drug Name | Actonel |
| PubMed Health | Antacid, Calcium Containing (By mouth) |
| Drug Classes | Antacid, Aluminum Containing, Antacid, Aluminum/Calcium/Magnesium Containing, Antacid, Calcium Containing, Antacid, Magnesium Containing, Antiflatulent, Calcium Supplement |
| Drug Label | ACTONEL (risedronate sodium) tablets is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each ACTONEL tablet for oral administration contains the equivalent of 5, 30, 35, 75, or 150 mg of anh... |
| Active Ingredient | Risedronate sodium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 5mg; 30mg; 150mg; 35mg |
| Market Status | Prescription |
| Company | Warner Chilcott |
| 2 of 6 | |
|---|---|
| Drug Name | Atelvia |
| Drug Label | Atelvia (risedronate sodium) delayed-release tablets contain a pH-sensitive enteric coating and a chelating agent (EDTA). Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each... |
| Active Ingredient | Risedronate sodium |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | 35mg |
| Market Status | Prescription |
| Company | Warner Chilcott |
| 3 of 6 | |
|---|---|
| Drug Name | Risedronate sodium |
| PubMed Health | Risedronate (By mouth) |
| Drug Classes | Calcium Regulator |
| Drug Label | ACTONEL (risedronate sodium) tablets is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each ACTONEL tablet for oral administration contains the equivalent of 5, 30, 35, 75, or 150 mg of anh... |
| Active Ingredient | Risedronate sodium |
| Dosage Form | Tablet |
| Route | oral; Oral |
| Strength | 30mg; 150mg; 75mg; 5mg; 35mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Apotex; Aurobindo Pharma; Teva Pharms Usa; Sun Pharma Global; Teva Pharms |
| 4 of 6 | |
|---|---|
| Drug Name | Actonel |
| PubMed Health | Antacid, Calcium Containing (By mouth) |
| Drug Classes | Antacid, Aluminum Containing, Antacid, Aluminum/Calcium/Magnesium Containing, Antacid, Calcium Containing, Antacid, Magnesium Containing, Antiflatulent, Calcium Supplement |
| Drug Label | ACTONEL (risedronate sodium) tablets is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each ACTONEL tablet for oral administration contains the equivalent of 5, 30, 35, 75, or 150 mg of anh... |
| Active Ingredient | Risedronate sodium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 5mg; 30mg; 150mg; 35mg |
| Market Status | Prescription |
| Company | Warner Chilcott |
| 5 of 6 | |
|---|---|
| Drug Name | Atelvia |
| Drug Label | Atelvia (risedronate sodium) delayed-release tablets contain a pH-sensitive enteric coating and a chelating agent (EDTA). Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each... |
| Active Ingredient | Risedronate sodium |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | 35mg |
| Market Status | Prescription |
| Company | Warner Chilcott |
| 6 of 6 | |
|---|---|
| Drug Name | Risedronate sodium |
| PubMed Health | Risedronate (By mouth) |
| Drug Classes | Calcium Regulator |
| Drug Label | ACTONEL (risedronate sodium) tablets is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each ACTONEL tablet for oral administration contains the equivalent of 5, 30, 35, 75, or 150 mg of anh... |
| Active Ingredient | Risedronate sodium |
| Dosage Form | Tablet |
| Route | oral; Oral |
| Strength | 30mg; 150mg; 75mg; 5mg; 35mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Apotex; Aurobindo Pharma; Teva Pharms Usa; Sun Pharma Global; Teva Pharms |
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 150MG
USFDA APPLICATION NUMBER - 20835
DOSAGE - TABLET;ORAL - 30MG
USFDA APPLICATION NUMBER - 20835
DOSAGE - TABLET;ORAL - 35MG
USFDA APPLICATION NUMBER - 20835
DOSAGE - TABLET;ORAL - 5MG
USFDA APPLICATION NUMBER - 20835
DOSAGE - TABLET;ORAL - 75MG **Federal Registe...DOSAGE - TABLET;ORAL - 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20835
DOSAGE - TABLET, DELAYED RELEASE;ORAL - 35MG
USFDA APPLICATION NUMBER - 22560
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ABOUT THIS PAGE
53
PharmaCompass offers a list of Risedronate Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Risedronate Sodium manufacturer or Risedronate Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Risedronate Sodium manufacturer or Risedronate Sodium supplier.
PharmaCompass also assists you with knowing the Risedronate Sodium API Price utilized in the formulation of products. Risedronate Sodium API Price is not always fixed or binding as the Risedronate Sodium Price is obtained through a variety of data sources. The Risedronate Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Risedronate Sodium Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Risedronate Sodium Hydrate, including repackagers and relabelers. The FDA regulates Risedronate Sodium Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Risedronate Sodium Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Risedronate Sodium Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Risedronate Sodium Hydrate supplier is an individual or a company that provides Risedronate Sodium Hydrate active pharmaceutical ingredient (API) or Risedronate Sodium Hydrate finished formulations upon request. The Risedronate Sodium Hydrate suppliers may include Risedronate Sodium Hydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Risedronate Sodium Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Risedronate Sodium Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Risedronate Sodium Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Risedronate Sodium Hydrate DMFs exist exist since differing nations have different regulations, such as Risedronate Sodium Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Risedronate Sodium Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Risedronate Sodium Hydrate USDMF includes data on Risedronate Sodium Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Risedronate Sodium Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Risedronate Sodium Hydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Risedronate Sodium Hydrate Drug Master File in Japan (Risedronate Sodium Hydrate JDMF) empowers Risedronate Sodium Hydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Risedronate Sodium Hydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Risedronate Sodium Hydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Risedronate Sodium Hydrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Risedronate Sodium Hydrate Drug Master File in Korea (Risedronate Sodium Hydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Risedronate Sodium Hydrate. The MFDS reviews the Risedronate Sodium Hydrate KDMF as part of the drug registration process and uses the information provided in the Risedronate Sodium Hydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Risedronate Sodium Hydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Risedronate Sodium Hydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Risedronate Sodium Hydrate suppliers with KDMF on PharmaCompass.
A Risedronate Sodium Hydrate CEP of the European Pharmacopoeia monograph is often referred to as a Risedronate Sodium Hydrate Certificate of Suitability (COS). The purpose of a Risedronate Sodium Hydrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Risedronate Sodium Hydrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Risedronate Sodium Hydrate to their clients by showing that a Risedronate Sodium Hydrate CEP has been issued for it. The manufacturer submits a Risedronate Sodium Hydrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Risedronate Sodium Hydrate CEP holder for the record. Additionally, the data presented in the Risedronate Sodium Hydrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Risedronate Sodium Hydrate DMF.
A Risedronate Sodium Hydrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Risedronate Sodium Hydrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Risedronate Sodium Hydrate suppliers with CEP (COS) on PharmaCompass.
A Risedronate Sodium Hydrate written confirmation (Risedronate Sodium Hydrate WC) is an official document issued by a regulatory agency to a Risedronate Sodium Hydrate manufacturer, verifying that the manufacturing facility of a Risedronate Sodium Hydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Risedronate Sodium Hydrate APIs or Risedronate Sodium Hydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Risedronate Sodium Hydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Risedronate Sodium Hydrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Risedronate Sodium Hydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Risedronate Sodium Hydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Risedronate Sodium Hydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Risedronate Sodium Hydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Risedronate Sodium Hydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Risedronate Sodium Hydrate suppliers with NDC on PharmaCompass.
Risedronate Sodium Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Risedronate Sodium Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Risedronate Sodium Hydrate GMP manufacturer or Risedronate Sodium Hydrate GMP API supplier for your needs.
A Risedronate Sodium Hydrate CoA (Certificate of Analysis) is a formal document that attests to Risedronate Sodium Hydrate's compliance with Risedronate Sodium Hydrate specifications and serves as a tool for batch-level quality control.
Risedronate Sodium Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Risedronate Sodium Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Risedronate Sodium Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Risedronate Sodium Hydrate EP), Risedronate Sodium Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Risedronate Sodium Hydrate USP).
